From left: Michael Thomas, Robyn Goforth; Misty Stevens, Paul Mlaker Jr.
Last year's contest winner, BiologicsMD, is thinking big. Chief medical officer Michael Thomas says that once the team develops its new osteoporosis treatment, the company will set its sights on other potentially life-saving breakthroughs that have been languishing in university research labs, just waiting for someone to embark on the long slog of taking them to market.
Thomas sees BiologicsMD creating a system for developing neglected inventions that come out of academia, and potentially becoming a major player in the field. But until the company gets farther along, he and the rest of the team will hold onto their day jobs.
Right now, the group hopes to complete its first phase of trials of its osteoporosis drug within three to four years. In addition to the $2.3 million grant from the Department of Defense, Thomas says BiologicsMD has also netted about half a million in additional funding from other sources.
NEXT: Rebellion Photonics
